How should a photodynamic therapy (PDT) LED device be used for dermatologic treatment, including photosensitizer application, illumination settings, eye protection, contraindications, and alternative options?

How to Use a PDT LED Device for Dermatologic Treatment

LED-based PDT devices should be used with either MAL (Metvix) or BF-200 ALA (Ameluz) photosensitizers, applying the prodrug after lesion preparation, followed by red light illumination at 630-635 nm with appropriate eye protection, while avoiding use in patients with porphyria or photosensitizer allergies. 1

Photosensitizer Selection and Application

The two licensed prodrugs in the UK are:

• MAL (Metvix): For non-hyperkeratotic actinic keratoses (AK), squamous cell carcinoma in situ (SCC in situ), and superficial basal cell carcinomas (BCC) 1
• BF-200 ALA (Ameluz): Currently the only licensed nano-colloidal ALA formulation 1

Pre-treatment preparation is critical: Adequate lesion preparation through paring or keratolytic agents significantly improves outcomes, particularly for hyperkeratotic lesions 2. Consider pre-treatment with fractional laser to enhance prodrug penetration 1.

LED Device Specifications and Settings

LED sources have become the preferred light source for PDT due to their advantages over lasers and broadband sources 2. Modern LED devices (such as Aktilite 16,128, or Omnilux) emit at 630-635 nm, matching the PpIX activation peak while excluding extraneous wavelengths, permitting shorter irradiation times 2.

Light Dosimetry Parameters:

• Wavelength: 630-635 nm for red light (deeper tissue penetration) 1, 2
• Standard dose: 37-100 J/cm² depending on indication 2
• Irradiance: Typically 50-100 mW/cm² 2
• Treatment duration: 7-12 minutes with conventional protocols 3

Critical caveat: Commercial PDT light sources often lack traceability to national measurement standards. In one study, delivered dose fell to just over one-third at only 2 cm from the central area 1. Position the device consistently and verify coverage of the entire treatment field.

Treatment Protocols by Indication

For Actinic Keratoses:

• One treatment session 1
• Consider blue light (417 nm) as alternative for superficial AK, though red light penetrates deeper 2

For BCC and SCC in situ:

• Two treatments, 7 days apart 1
• Red light superior to blue/green for these deeper lesions 2
• Fractionated illumination improves outcomes: Divide light dose into two exposures with a dark interval to allow tissue reoxygenation and increased reactive oxygen species generation 4

Incubation Times:

• Standard protocol: 3-4 hours after photosensitizer application before illumination 1, 2
• Daylight PDT alternative: 30 minutes incubation followed by continuous daylight exposure (nearly pain-free) 3, 5
• Extended incubation beyond standard times causes more pain without clear benefit 3

Mandatory Safety Measures

Eye Protection:

Goggles must be worn by both patient and staff to limit transmission of high-intensity light and avoid retinal damage, discomfort, and color perception disturbance 2. While blue light poses the greatest retinal hazard, protective eyewear is recommended for all wavelengths used in PDT 2.

Absolute Contraindications:

• History of porphyria 2
• Allergy or photoallergy to photosensitizer ingredients 2

Post-Treatment Precautions:

Localized photosensitivity persists up to 48 hours after treatment. ALA degrades with a half-life of approximately 24 hours, and MAL-induced PpIX clears from normal skin within 24-48 hours 2.

Pain Management

Pain is the most significant acute adverse effect, particularly with high-irradiance regimens 1. Predictive factors for severe pain include:

• Larger treatment areas
• Field-change photodamage
• Head and neck locations 1

Daylight PDT dramatically reduces pain compared to conventional LED-based PDT by activating PpIX continuously as it forms, rather than allowing accumulation 3, 5. Traditional pain relief methods (topical analgesics, cold air, pausing irradiation) have limited impact, though nerve blockade may be more effective 1.

Expected Outcomes and Adverse Effects

Normal Treatment Response:

• Erythema and edema (expected inflammatory response, not adverse effect) 1
• Occasional frank urticaria 1
• Excellent cosmetic outcomes compared to other modalities 1

Uncommon Effects:

• Hyper- or hypopigmentation lasting weeks to months 1
• Scarring (rare event) 1
• Localized hair loss (more common with BCC than Bowen's disease) 2

Carcinogenicity Risk:

PDT has low carcinogenic potential - it does not induce DNA covalent modifications, cyclobutane pyrimidine dimers, or (6-4) photoproducts characteristic of UV radiation 2. Only three cases of possible PDT-related skin cancer have been reported in the literature 2.

Alternative and Enhanced Approaches

Combination treatments improve efficacy: Adding microdermabrasion, microneedling, curettage, or various lasers before PDT enhances clinical outcomes and cosmetic results 6. For aesthetic applications, 2-3 treatment cycles typically provide optimal results, with full effects evident 3-6 months post-treatment 5.

Ambulatory PDT using lightweight portable LED devices represents an emerging delivery method to facilitate treatment outside hospital settings 1.